35th Annual Leland R Cowan Cancer Symposium: Update on Diagnosis and Treatment of Melanoma February 4, 2017
AJCC 7th Edition Staging of Malignant Melanoma: TX: can’t be assessed, eg curettage or regressed melanoma • T0: No evidence of primary tumor • Tis: melanoma in situ • T1: < 1mm thick • a=no ulceration, <1sq mm, b=with ulceration, >1sq mm • T2: 1.01-2mm thick • a = no ulceration, b = with ulceration • T3: 2.01-4mm thick • a = no ulceration, b = with ulceration • T4: > 4mm thick • a = no ulceration, b = with ulceration •
AJCC 7th Edition Staging of Malignant Melanoma: • NX: Regional nodes can’t be assessed • N0: No regional metastases detected • N1: 1 node with metastatic disease • a=micrometastasis, b=macrometastasis • N2: 2-3 + nodes • a=micro, b=macro, c=in transit met, without nodal metastases • N3: 4 or more metastatic nodes, or matted nodes or in transit met with metastatic nodes
AJCC 7th Edition Staging of Malignant Melanoma: • M0: No evidence of distant metastases • M1a: Metastases to skin, subcutaneous or distant lymph nodes • M1b: Metastases to lung • M1c: Metastases to all other visceral sites or elevated LDH
Stage Groupings, Clinical: • Stage 0: Tis N0 M0 • IA: T1a N0 M0 • IB: T1b, T2a, N0 M0 • IIA: T2b, T3a, N0 M0 • IIB: T3b, T4a, N0 M0 • IIC: T4b N0 M0 • III: Any T N>1 M0 • IV: Any T Any N M1
Pathologic Stage Grouping: • 0-IIC are exactly the same as clinical staging • IIIA: T1-4a N1a, 2a M0 • IIIB: T1-4b N1a, N2a M0 • T1-4a N1b, N2b, N2c M0 • IIIC: T1-4b N1b, N2b, N2c M0 • Any T N3 M0 • IV: Any T Any N M1
Recommend
More recommend